Figure 1
Survival estimate from diagnosis of PMF patients who become intermediate-2 and high risk IPSS with a blast cell count <10% at any time of their follow-up according to the COMFORT-2 (n = 100) and DIPSS (N = 350) cohorts.
Survival estimate from diagnosis of PMF patients who become intermediate-2 and high risk IPSS with a blast cell count <10% at any time of their follow-up according to the COMFORT-2 (n = 100) and DIPSS (N = 350) cohorts.
